Antiparkinsonian drugs and their neuroprotective effects

Biological & Pharmaceutical Bulletin
Yoshihisa KitamuraTakashi Taniguchi

Abstract

In Parkinson's disease, while dopamine (DA) replacement therapy, such as with L-DOPA (levodopa), improves the symptoms, it does not inhibit the degeneration of DA neurons in the substantia nigra. Numerous studies have suggested that both endogenous and environmental neurotoxins and oxidative stress may participate in this disease, but the detailed mechanisms are still unclear. Recent genetic studies in familial Parkinson's disease and parkinsonism have shown several gene mutations. This new information regarding its pathogenesis offers novel prospects for effective strategies involving the neuroprotection of vulnerable DA neurons. This review summarizes current findings regarding the pathogenesis and antiparkinsonian drugs, and discusses their possibilities of targets to develop novel neuroprotective drugs.

References

Sep 29, 1989·Biochemical and Biophysical Research Communications·Y MizunoY Kagawa
Jan 1, 1986·Clinical Neuropharmacology·J W Langston, I Irwin
May 24, 1995·Biochimica Et Biophysica Acta·Y MizunoT Ozawa
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K UédaT Saitoh
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·K Z ZhangL C Andersson
Mar 21, 1996·Nature·D M GashG A Gerhardt
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·S PrzedborskiT M Dawson
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·D AcciliS Fuchs
Jul 18, 1996·European Journal of Pharmacology·M GassenM B Youdim
Sep 6, 1996·Neuroscience Letters·M MogiT Nagatsu
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·J P SteinerP D Suzdak
Apr 11, 1997·Science·R H ZetterströmT Perlmann
May 1, 1997·Trends in Pharmacological Sciences·J J HaganG H Poste
May 20, 1998·Proceedings of the National Academy of Sciences of the United States of America·D OffenO Bernard
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Aug 28, 1998·Science·D R Green, J C Reed
Oct 8, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Oct 15, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Oct 17, 1998·Nature·E LeroyM H Polymeropoulos
Nov 6, 1998·Japanese Journal of Pharmacology·Y KitamuraT Taniguchi

❮ Previous
Next ❯

Citations

Aug 21, 2003·Trends in Molecular Medicine·Shun ShimohamaTakashi Taniguchi
Oct 12, 2010·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yoshihisa Kitamura
Apr 28, 2005·Brain Research·Fabio García-GarcíaJames M Krueger
Jan 31, 2006·Trends in Neurosciences·Yuri Bozzi, Emiliana Borrelli
Jul 2, 2003·Journal of Pharmacological Sciences·Yoshihisa KitamuraKenji Watanabe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.

Related Papers

Japanese Journal of Pharmacology
Y KitamuraT Taniguchi
Seminars in Cell & Developmental Biology
Kiyokazu Agata, K Watanabe
© 2022 Meta ULC. All rights reserved